Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms

Journal of Clinical Medicine

MichaelJ. Boyer¹  WendyA. Cooper¹  Steven Kao¹  MeganB. Barnet² 

[1] Sydney Medical School, The University of Sydney, Camperdown, NSW 2006, Australia;The Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia;

关键词: non-small cell lung cancer;    immunotherapy;    checkpoint inhibitors;   

DOI  :  10.3390/jcm7060151

来源: DOAJ

【 摘 要 】

Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where “best-case” scenario has long been inadequate. This progress has highlighted the immunogenic nature of NSCLC and invigorated research into immunotherapy in the field. In this review we consider the foundations of immunotherapy in NSCLC, canvass the current research and summarise the evidence guiding clinical practice.

【 授权许可】

Unknown